TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors
Brief Summary: Objectives:

* Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT)
* Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in the study population of atherosclerosis patients.


Options:
A: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?
Brief Summary: The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (CABG) compared to aspirin alone.


Options:
A: Intervention Type: DRUG; Name: clopidogrel and metoprolol; Assigned to Arm(s): N/A
B: Arm Label: 75mg Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 mg daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: water pill daily | Intervention Type: DRUG; Name: Clopidogrel 75 mg daily; Assigned to Arm(s): 75mg Clopidogrel | Intervention Type: DRUG; Name: water pill daily; Assigned to Arm(s): Placebo
C: Arm Label: aspirin+placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: aspirin + placebo | Arm Label: aspirin+pregrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + pregrel (Clopidogrel resinate) | Arm Label: Aspirin+Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + plavix (Clopidogrel bisulfate) | Intervention Type: DRUG; Name: aspirin + pregrel (Clopidogrel resinate); Assigned to Arm(s): aspirin+pregrel | Intervention Type: DRUG; Name: aspirin + placebo; Assigned to Arm(s): aspirin+placebo | Intervention Type: DRUG; Name: aspirin + plavix (Clopidogrel bisulfate); Assigned to Arm(s): Aspirin+Plavix
D: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin,Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive.
Brief Summary: To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy.

To verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe.

To collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with GERD.


Options:
A: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
B: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid; Assigned to Arm(s): 1, 2, 3
D: Intervention Type: DRUG; Name: Esomeprazole (Nexium); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive.
Brief Summary: To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy.

To verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe.

To collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with GERD.


Options:
A: Intervention Type: DRUG; Name: Esomeprazole (Nexium); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid; Assigned to Arm(s): 1, 2, 3
C: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo
D: Arm Label: Rabeprazole sodium 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rabeprazole sodium 5 mg | Arm Label: Rabeprazole sodium 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Rabeprazole sodium 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rabeprazole sodium 5 mg; Assigned to Arm(s): Rabeprazole sodium 5 mg | Intervention Type: DRUG; Name: Rabeprazole sodium 10 mg; Assigned to Arm(s): Rabeprazole sodium 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive


Options:
A: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: RWJ-333369; Assigned to Arm(s): N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: RWJ 333369 | Intervention Type: DRUG; Name: RWJ 333369; Assigned to Arm(s): 001
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Carisbamate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Carisbamate; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Carisbamate; Assigned to Arm(s): 002

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized Double-Blind Study Of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia
Brief Summary: The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug \[form\] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
C: Arm Label: Ceftobiprole medocaril; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole medocaril | Arm Label: IV standard-of-care cephalosporin; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV standard-of-care cephalosporin | Intervention Type: DRUG; Name: ceftobiprole medocaril; Assigned to Arm(s): Ceftobiprole medocaril | Intervention Type: DRUG; Name: IV standard-of-care cephalosporin; Assigned to Arm(s): IV standard-of-care cephalosporin
D: Arm Label: Ampicillin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin | Arm Label: Amoxicillin arm; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Amoxicillin arm, Ampicillin arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized Double-Blind Study Of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia
Brief Summary: The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug \[form\] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
B: Intervention Type: DRUG; Name: doripenem; Assigned to Arm(s): N/A
C: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study Of The Efficacy And Safety Of Dapoxetine In The Treatment Of Subjects With Premature Ejaculation
Brief Summary: The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).


Options:
A: Intervention Type: DRUG; Name: dapoxetine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-Center, Open Label Trial to Establish the Therapeutic Equivalence Between GerEpo and Eprex® and to Determine the Long Term Safety Profile of GerEpo in Patients on Hemodialysis.
Brief Summary: The purpose of the study is to establish the equivalence of GerEpo with the standard treatment Eprex® for a treatment period of 12 weeks in patients on Hemodialysis with respect to hemoglobin response and to establish the longer-term safety profile of GerEpo, with special regards for the occurrence of Pure Red Cell Aplasia (PRCA) and other immunogenicity related adverse event


Options:
A: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: GerEPO; Assigned to Arm(s): N/A
C: Arm Label: Group 1 (Early Epoetin Beta); Type: EXPERIMENTAL; Interventions: Drug: Epoetin beta | Arm Label: Group 2 (No/Late Epoetin Beta); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Group 1 (Early Epoetin Beta), Group 2 (No/Late Epoetin Beta)
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-Center, Open Label Trial to Establish the Therapeutic Equivalence Between GerEpo and Eprex® and to Determine the Long Term Safety Profile of GerEpo in Patients on Hemodialysis.
Brief Summary: The purpose of the study is to establish the equivalence of GerEpo with the standard treatment Eprex® for a treatment period of 12 weeks in patients on Hemodialysis with respect to hemoglobin response and to establish the longer-term safety profile of GerEpo, with special regards for the occurrence of Pure Red Cell Aplasia (PRCA) and other immunogenicity related adverse event


Options:
A: Intervention Type: DRUG; Name: GerEPO; Assigned to Arm(s): N/A
B: Arm Label: Epoetin Hospira; Type: OTHER; Interventions: Biological: Epoetin Hospira Arm, Drug: IV Iron | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care Arm, Drug: IV Iron | Intervention Type: BIOLOGICAL; Name: Epoetin Hospira Arm; Assigned to Arm(s): Epoetin Hospira | Intervention Type: OTHER; Name: Standard of Care Arm; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Epoetin Hospira, Standard of Care
C: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo (Epoetin delta) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Intervention Type: DRUG; Name: Dynepo (Epoetin delta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.
Brief Summary: This study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.


Options:
A: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039) | Arm Label: PIP/TAZ-AMC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid | Intervention Type: DRUG; Name: Moxifloxacin (Avelox, BAY12-8039); Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid; Assigned to Arm(s): PIP/TAZ-AMC
B: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: ceftaroline, Drug: Placebo | Arm Label: IV Vancomycin plus IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: vancomycin plus aztreonam | Intervention Type: DRUG; Name: ceftaroline; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: vancomycin plus aztreonam; Assigned to Arm(s): IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ceftaroline fosamil for Injection
C: Intervention Type: DRUG; Name: MK0826, ertapenem sodium / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A
D: Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Arm Label: CEM-102 Regimen A; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Arm Label: CEM-102 Regimen B; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen A | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MK0476 Phase II/III Placebo Controlled Double Blind Study
Brief Summary: This study evaluates the efficacy and safety of MK0476 intravenous administration in adult patients with acute asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MN-221 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MN-221; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: heliox; Type: EXPERIMENTAL; Interventions: Other: HELIOX | Arm Label: heliox+posture; Type: EXPERIMENTAL; Interventions: Other: HELIOX+POSTURE | Arm Label: oxygen+posture; Type: EXPERIMENTAL; Interventions: Other: OXYGEN + POSTURE | Arm Label: oxygen; Type: ACTIVE_COMPARATOR; Interventions: Other: OXYGEN | Intervention Type: OTHER; Name: HELIOX; Assigned to Arm(s): heliox | Intervention Type: OTHER; Name: OXYGEN; Assigned to Arm(s): oxygen | Intervention Type: OTHER; Name: HELIOX+POSTURE; Assigned to Arm(s): heliox+posture | Intervention Type: OTHER; Name: OXYGEN + POSTURE; Assigned to Arm(s): oxygen+posture
D: Arm Label: EzPAP; Type: EXPERIMENTAL; Interventions: Drug: EzPAP | Arm Label: Standard care; Type: SHAM_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: DRUG; Name: EzPAP; Assigned to Arm(s): EzPAP | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard care

Answer: A